Figure 5
Therapeutic effect of radioinducible IL-12 gene therapy after 6 Gy irradiation in mouse TS/A tumors. EP, electroporation; IR, irradiation; p21, intratumoral injection of the p21-mIL-12 plasmid; p21 + EP, gene electrotransfer of the p21-mIL-12 plasmid; p21 + EP + IR, radio-gene therapy with the p21-mIL-12 plasmid; pORF, intratumoral injection of the pORF-mIL-12 plasmid, pORF + EP, gene electrotransfer of the pORF-mIL-12 plasmid; etc. (a) DT, doubling time i.e. time needed for the tumor to double in size; GD, growth delay i.e. difference between the doubling time of the specific experimental group and average doubling time of the control groups); CR, complete response i.e. complete disappearance of the tumor lasting for 100 days; N, number of the animals in the individual experimental group; data are presented as mean ± SEM;*, P < 0.05 vs. control. (b) Tumor growth curves after radioinducible IL-12 gene therapy. The data were pooled from 2 independent experiments with 18–10 animals in each experimental group and are presented as means with the standard errors of the mean. (c) Serum and (d) intratumoral IL-12 protein concentrations and (e) intratumoral Il-12 mRNA levels on the 5th day after the induction with irradiation. Each column represents mean + SEM. (c) *, P < 0.05 vs. control, 6–9 animals per experimental group. (d) *, P < 0.05 vs. all experimental groups except pORF + EP, 2–3 animals per experimental group. (e) *, P < 0.05 vs. control, 2–3 animals per experimental group.